This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -128.57% and 2.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.
Insulet (PODD) to Expand Base in Malaysia With New Facility
by Zacks Equity Research
The new manufacturing facility by Insulet (PODD) is set to have approximately 400,000 square feet of manufacturing space.
Insulet (PODD) Q1 Earnings Surpass Estimates, Margins Grow
by Zacks Equity Research
Robust adoption of Omnipod DASH and record new customer starts have contributed to Insulet's (PODD) Q1 performance.
Insulet (PODD) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 73.91% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stocks' Earnings May 5 Roster: MCK, CAH & PODD
by Debanjana Dey
The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.
Refresh Your Portfolio by Dumping These 5 Toxic Stocks
by Rimmi Singhi
Get rid of toxic stocks like GoodRx (GDRX), Insulet (PODD), Vonage (VG), AppLovin (APP) and Embraer (ERJ) to avoid portfolio bleeding.
Here's Why You Should Hold on to Insulet (PODD) Stock For Now
by Zacks Equity Research
Investors are optimistic about Insulet (PODD) on robust uptake of the Omnipod system and bullish guidance.
Insulet (PODD) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Insulet (PODD) Stock For Now
by Zacks Equity Research
Investors are optimistic about Insulet's (PODD) robust uptake of the Omnipod system both in the U.S. and international markets.
Insulet (PODD) Product Volume Up, COVID-Led Softness Persists
by Zacks Equity Research
Insulet's (PODD) drug delivery revenues surge led by increased production volumes, driven by higher-than-expected demand from its partner.
Insulet (PODD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.
Insulet (PODD) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 40% and 2.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 8.70% and 1.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.
Insulet (PODD) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.
Insulet (PODD) Misses Q3 Earnings Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of -9.09% and 1.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued strength in Aurora Cannabis' (ACB) domestic-adult-recreational segment is expected to have driven Q1 sales.
Is a Surprise Coming for Insulet (PODD) This Earnings Season?
by Zacks Equity Research
Insulet (PODD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Clover Health (CLOV) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Clover Health's (CLOV) third-quarter results are likely to benefit from Direct Contracting and strategic partnerships.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital approach to administering vaccines across the nation is expected to have strongly contributed to its Q3 performance.
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Strong surgeon registrations of the Signature One surgical planning system for shoulder procedures are likely to have driven Zimmer Biomet's (ZBH) growth in Q3.
Insulet (PODD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strong gains from the recent Cantel Medical buyout as well as the addition of a new Dental arm are expected to have contributed STERIS' (STE) Q2 performance.